The exploration of the efficacy and possible mechanisms of paroxetine combined with liraglutide in the treatment of depression associated with obesity.

Start Date28 Nov 2025

Sponsor / Collaborator

Southeast University Affiliated Zhonda Hospital

NCT07070232

/ RecruitingPhase 1/2

A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after prior therapy.

Start Date12 Aug 2025

Sponsor / Collaborator

BioNTech SE

[+1]

NCT07057011

/ Not yet recruitingNot ApplicableIIT

Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy in Premature Ejaculation Patients With the Serotonin Transporter Gene Polymorphism (SLC6A4)

Premature ejaculation (PE) is a prevalent male sexual dysfunction that affects as many as 20-30% of men regardless of age and ethnicity.The International Society for Sexual Medicine defines premature ejaculation as a male sexual dysfunction characterised by ejaculation that always or nearly always occurs before or within about 1 minute of vaginal penetration from the first sexual experience (lifelong premature ejaculation) or a clinically significant and bothersome reduction in latency time, often to about 3 minutes or less (acquired premature ejaculation), the inability to delay ejaculation on all or nearly all vaginal penetrations and with negative personal consequences include distress, bother, frustration, and avoidance of sexual intimacy.

Start Date01 Jul 2025

Sponsor / Collaborator

South Valley University

100 Clinical Results associated with Paroxetine Hydrochloride

100 Translational Medicine associated with Paroxetine Hydrochloride

100 Patents (Medical) associated with Paroxetine Hydrochloride

4,785

Literatures (Medical) associated with Paroxetine Hydrochloride

02 Nov 2025·Expert Opinion On Drug Safety

Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database

Article

Author: Zhang, Rui ; Li, Dongxuan ; Du, Qian ; Zhu, Jun ; Wang, Yalan ; Dai, Liyang ; Liu, Songqing ; Zhang, Tongyan ; Wu, Fan

BACKGROUND:

The comprehensive quantitative and comparative risk data of drug-induced erectile dysfunction (ED) are still lacking, and this study aims to supplement this information.

RESEARCH DESIGN AND METHODS:

We reviewed all the ED reports in the FDA Adverse Event Reporting System (FAERS) database from 2004 to 2023 and summarized a potential ED culprit-drug list and its corresponding reporting frequency. The reporting odds ratio (ROR) method was used to conduct disproportionality analysis.

RESULTS:

A total of 20,098 ED reports were retrieved from the FAERS database, which recorded 734 different ED culprit-drugs, involving 74 drug classes. Finasteride was the drug with the highest reporting frequency, and urologicals was the drug class with the highest reporting frequency. In disproportionality analysis, 209 drugs with positive signals showed a close relationship with ED occurrence, among which finasteride was the drug with the highest signal strength. Among 209 drugs with positive signals, 27 were compound preparations, and the risk level of compound preparations was usually higher than their single active ingredient.

CONCLUSIONS:

Our study integrated quantitative and comparative ED risk data of 734 drugs by using the FAERS database, which can provide reference information for regulators, medical personnel, and others involved in drug management and use.

01 Oct 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Immobilization of human myeloperoxidase on silica gel for inhibitors assessment

Article

Author: Kauffmann, Jean-Michel ; Delporte, Cédric ; Zouaoui Boudjeltia, Karim ; Van Antwerpen, Pierre ; Parsajoo, Yalda Cobra

Myeloperoxidase (MPO), a hemo-protein present in neutrophils and monocytes, significantly contributes to immune responses against microbial pathogens. Increased MPO activity, however, promotes the production of highly reactive oxidized species in extracellular fluids that can damage host tissues causing inflammatory events. To explore the potential of MPO as a target for inhibitor screening, this study aimed to develop and evaluate a mini-reactor system based on immobilized MPO. Several immobilization strategies including physical adsorption and covalent binding, were tested using silica gel as the support material. Among them, immobilization via cyanogen bromide (CNBr) activation was selected as the optimal method based on long-term stability (> 90 % after 20 runs) and a relative activity of 60 % after immobilization. Kinetic parameters for H₂O₂ were determined to characterize the enzymatic behavior post-immobilization, including K_mapp and V_max (46 ± 4 µM and 463 ± 38 µM/min, respectively). The system was then employed to evaluate the inhibitory potency (IC₅₀) of three model compounds-salicylhydroxamic acid (SHA), paroxetine (PARO), and 4-aminobenzohydrazide (4-ABAH)-on HOCl production in the presence of 10 µM H₂O₂. 4-ABAH emerged as the most potent irreversible inhibitor (IC₅₀ = 0.30 µM), while SHA was the least effective (IC₅₀ = 27.10 µM). Those results demonstrated that immobilized-MPO preserved its activity and exhibited good stability. This mini-reactor provides a reliable platform for inhibitor studies, offering potential applications in screening therapeutic compounds to mitigate MPO-related inflammatory conditions.

02 Sep 2025·Therapeutic Delivery

Dissolving microneedle patches for transdermal delivery of paroxetine: in-vitro, ex-vivo studies and its PBPK modeling

Article

Author: Shoaib, Muhammad Harris ; Sikandar, Muhammad ; Irshad, Asma ; Siddiqui, Fahad ; Saleem, Muhammad Talha ; Yousuf, Rabia Ismail ; Ahmed, Farrukh Rafiq

BACKGROUND:

Paroxetine HCl (PRX-HCl), an antidepressant, has poor water solubility and low oral bioavailability with 50% being metabolized in the liver. The oral formulations have multiple side effects. The present work aimed to develop dissolving microneedle patches (MNPs) of PRX-HCl to resolve low bioavailability and side effect issues while achieving enhanced transdermal delivery.

MATERIALS AND METHODS:

Three silicone templates of varying dimensions were used to fabricate 27 blank and nine PRX-HCl MNPs with PVP and PVA through mold casting method. MNPs were evaluated for physicochemical properties, in-vitro release, and ex-vivo permeation. The optimized MNP was further analyzed for FTIR, DSC, skin penetration, in-silico PBPK modeling, and stability.

RESULTS:

MNPs from the optimized formulation successfully created microchannels in rat skin, demonstrated higher permeation than control MNPs with a flux of 146.18 ± 13.42 µg/cm²/h, presented a decrease in lag phase and an increase in drug plasma C_max and AUC compared to PAXIL CR 12.5 mg oral, and showed higher stability in the room and refrigerator conditions.

CONCLUSION:

The prepared MNPs were stable and can deliver PRX-HCl sufficiently across skin barrier with enhanced bioavailability compared to oral administration at similar doses and thus be a better alternative to already available delivery systems for PRX-HCl.

News (Medical) associated with Paroxetine Hydrochloride

30 Jan 2026

·www.einpresswire.com

Alternative to Meds Center Provides Clinical Education on Paxil Withdrawal and Individualized Discontinuation Support

Understanding Paxil withdrawal symptoms, tapering considerations, and patient-specific care Because paroxetine leaves the body quickly, even small dose changes or missed doses can trigger noticeable symptoms. This is why individualized tapering and close monitoring are so important.” — Alternative to Meds Center SEDONA, AZ, UNITED STATES, January 30, 2026 / EINPresswire.com / -- Alternative to Meds Center, a licensed residential mental health treatment facility located in Sedona, Arizona, is providing clinical education on Paxil (paroxetine) withdrawal, a frequently challenging experience for individuals seeking to discontinue selective serotonin reuptake inhibitor (SSRI) antidepressant medications. Paxil, known generically as paroxetine, is prescribed for a range of mental health conditions, including major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder. While many individuals initially experience symptom relief, others find that side effects, tolerance, or diminished benefit over time lead them to consider discontinuation. Clinical evidence shows that stopping paroxetine without appropriate medical guidance can result in significant withdrawal symptoms, particularly due to the medication’s short half-life and strong effect on serotonin regulation. Paroxetine withdrawal, often described as antidepressant discontinuation syndrome, may involve a wide range of physical, neurological, and psychological symptoms. Commonly reported effects include dizziness, nausea, headaches, flu-like symptoms, sleep disturbances, vivid dreams or nightmares, irritability, anxiety, and sensory disturbances such as “brain zaps” or electric shock–like sensations. Some individuals also report mood instability, confusion, panic attacks, or intrusive thoughts during withdrawal. “ Paxil withdrawal can be particularly intense compared to other SSRIs,” said a clinical representative for Alternative to Meds Center. “Because paroxetine leaves the body quickly, even small dose changes or missed doses can trigger noticeable symptoms. This is why individualized tapering and close monitoring are so important.” Medical literature indicates that withdrawal symptoms from paroxetine often begin within one to three days after a dose reduction or discontinuation. While some individuals experience symptoms that resolve within a few weeks, others report prolonged or fluctuating withdrawal lasting several months or longer, particularly after long-term use. In more severe cases, individuals may experience post-acute withdrawal symptoms that require ongoing support. Paroxetine works by blocking the reuptake of serotonin in the brain, increasing its availability in the synapse. Over time, the central nervous system adapts to this altered chemical environment, a process known as neuroadaptation. When the medication is reduced too rapidly or stopped abruptly, serotonin signaling can change suddenly, placing stress on the nervous system and contributing to withdrawal symptoms. Because of this mechanism, abrupt discontinuation is widely discouraged. Alternative to Meds Center emphasizes that withdrawal symptoms are often mistaken for relapse of the original mental health condition. This overlap can lead to misdiagnosis and unnecessary medication escalation. Distinguishing withdrawal physiology from recurrence of symptoms is a critical component of safe and effective care. Side effects are another reason many individuals choose to discontinue Paxil. Reported adverse effects include drowsiness, sexual dysfunction, weight changes, emotional blunting, agitation, and sleep disruption. In some cases, more serious risks such as increased suicidality or serotonin syndrome have been documented, particularly when paroxetine is combined with other serotonergic medications. These risks underscore the importance of informed decision-making and professional oversight. At Alternative to Meds Center, care for Paxil withdrawal focuses on individualized assessment and comprehensive support rather than standardized tapering schedules alone. Treatment planning considers factors such as medication history, physical health, nutritional status, stress physiology, and emotional well-being. Clinical care may include medical monitoring, psychotherapy, nutritional and orthomolecular support, stress-reduction strategies, and integrative therapies designed to support nervous system stability during tapering. The center also recognizes that not everyone requires inpatient treatment to discontinue Paxil. However, individuals who have experienced severe withdrawal symptoms, repeated unsuccessful tapering attempts, or significant functional impairment may benefit from a higher level of care. Choosing practitioners who are familiar with SSRI withdrawal is considered essential to reduce risk and improve outcomes. Located in the red rock region of Sedona, Alternative to Meds Center has nearly two decades of experience helping individuals safely reduce or discontinue psychiatric medications while addressing underlying contributors to mental health distress. The center’s residential programs are staffed by licensed medical and therapeutic professionals and are designed to provide a calm, structured environment focused on long-term recovery rather than short-term symptom suppression. As awareness of antidepressant withdrawal continues to grow, Alternative to Meds Center aims to provide evidence-based education that empowers individuals and families to make informed healthcare decisions. The center encourages anyone considering changes to their medication regimen to seek professional guidance and to avoid abrupt adjustments without medical supervision. More information about Paxil withdrawal, SSRI discontinuation, and available treatment options can be found through Alternative to Meds Center. About Alternative to Meds Center Alternative to Meds Center is a licensed residential mental health treatment facility based in Sedona, Arizona. For nearly 20 years, the center has helped individuals safely reduce or discontinue psychiatric medications while addressing underlying mental health challenges through medical supervision, psychotherapy, nutritional support, and holistic therapies. Alternative to Meds Center Alternative to Meds Center +1 877-503-0770 email us here Visit us on social media: LinkedIn Instagram Facebook YouTube TikTok X Other Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

28 Oct 2025

·www.businesswire.com

Wisp Launches Comprehensive Migraine Care Vertical, Innovating Category with First-Ever, Asynchronous Care

NEW YORK--(BUSINESS WIRE)--Wisp, the largest pure play women's telehealth company in the U.S., today announced the launch of a dedicated migraine care vertical, consisting of online consults, prescription medications, and ongoing follow-up to help patients manage and prevent migraines. Wisp’s migraine specialists, certified by the National Headache Foundation, create customized treatment plans, expanding access to affordable, convenient care for patients wherever they are. Migraines affect one in five women — occurring nearly three times as often in women as in men — yet timely access to care remains a major barrier. On average, patients wait 34 days to see a neurologist, and in some cases, more than 90 days. Wisp’s new offering enables patients to receive care in 72 hours or less. “Migraine care is the natural next step for Wisp,” said Monica Cepak, CEO of Wisp. “Only one in four adults with episodic migraines receive diagnosis and treatment, and our patients continue to ask for treatment options. We’re delivering on our promise, with diagnoses made online, to democratize access to care, breaking down barriers so women can enjoy more pain-free days without the long wait times or high costs.” Wisp’s migraine care program includes: Migraine Consults ($60): Initial consults repeat every 6 weeks until the patient is on a stable dose. Quarterly Check-Ins ($30): Once stabilized, patients check in every 3 months for prescription refills. Prescriptions for Immediate Relief: Imitrex (Sumatriptan), Maxalt (Rizatriptan), Zomig ODT (Zolmitriptan). Anti-Nausea Medications: Zofran ODT (Ondansetron), Reglan (Metoclopramide). Preventive Medications: Topamax (Topiramate), Toprol XL (Metoprolol XL), Elavil (Amitriptyline), Lexapro (Escitalopram), Paxil (Paroxetine), Effexor ER (Venlafaxine ER). Patients begin with a $60 consult, complete a short intake form, and upload brief videos to help diagnose and assess eligibility. From there, a licensed provider reviews their medical history and intake to recommend a treatment plan, which may include immediate relief, anti-nausea, or preventive medications. Prescriptions are then sent the same day to the patient’s local pharmacy, with no insurance needed. “Migraines can be incredibly disruptive, but they are also very manageable with the right treatment plan,” said Dr. Jennifer Peña, Chief Medical Officer at Wisp. “Our approach provides patients with timely access to providers, tailored treatment options, and ongoing support so they feel empowered to take control of their health.” This launch follows Wisp’s recent expansion of its weight care vertical, furthering the company’s mission to provide affordable and accessible care for women across all life stages. From sexual and reproductive health to at-home diagnostics, fertility, menopause, to weight care and now migraine management, Wisp is continuing to build the most comprehensive platform designed for the unique needs of women. About Wisp: Wisp is the largest pure play women’s telehealth provider in the U.S., serving more than 1.5 million patients nationwide. Offering discreet, online care and a comprehensive range of first-to-market products, Wisp addresses women’s health needs across every stage of life—from birth control to fertility, menopause, STI testing, and more. Recognized by Fast Company as one of the Most Innovative Companies of 2023 and by Inc. as Best in Business 2024, Wisp is majority-owned by WELL Health Technologies Corp. Visit hellowisp.com or follow @hellowisp on social media.

27 Oct 2025

·www.sciencedaily.com

Scientists discover a surprising way to quiet the anxious mind

Generalized anxiety disorder affects millions, often trapping sufferers in cycles of fear and isolation that conventional medications barely relieve. At UCSF, neuroscientist Jennifer Mitchell is testing a pharmaceutical form of LSD called MM120, which has shown striking results in reducing symptoms by promoting neuroplasticity and easing rigid thought patterns. In clinical trials, a single dose significantly outperformed standard treatments, offering hope to those who have found little relief elsewhere. Roughly one in twenty adults in the United States lives with generalized anxiety disorder (GAD). For those with severe symptoms, daily life can become overwhelming. Many avoid leaving home, struggle to maintain employment, and find it difficult to build meaningful social connections. Unfortunately, traditional medications often provide little relief. At the University of California, San Francisco (UCSF), neuroscientist Jennifer Mitchell, PhD, is leading research into innovative treatments for conditions such as anxiety, depression, PTSD, impulsivity, stress, and addiction. She believes a new approach could help where standard therapies fall short -- and early results are encouraging. This potential breakthrough treatment? A carefully developed pharmaceutical form of LSD. What is generalized anxiety disorder? Generalized anxiety disorder is a persistent and excessive form of anxiety that feels out of proportion to actual events or situations. It interferes with daily functioning, affecting relationships, work, and overall quality of life. People living with GAD may struggle to focus, make decisions, or remember information, making it difficult to manage responsibilities at work or home. The condition can also lead to fatigue, irritability, and secondary depression. Many individuals hesitate to leave their homes for fear of feeling trapped, embarrassed, or helpless in social or public settings. How is it different from day-to-day anxiety? A hallmark of generalized anxiety disorder is that it manifests as physical symptoms. Persistent worry activates the body's fight-or-flight response, triggering stress hormones that cause physical effects. Patients may have muscle tension and rapid breathing, and report symptoms like headaches and insomnia, ringing in the ears, and cardiovascular, respiratory, and gastrointestinal issues. How is generalized anxiety disorder treated? It's usually treated with medications like Zoloft and Paxil that boost and stabilize the neurotransmitter serotonin, leading to reduced anxiety and enhanced emotional well-being. These medications have been found to reduce symptoms by an average of 1.25 points on the 56-point anxiety scale -- insufficient to make significant difference for at least some patients. Why LSD? LSD as well as other psychedelics, have tremendous potential to shift mood and emotions when used in a controlled, therapeutic setting. We have seen this in a previous trial of Ecstasy to treat PTSD. The pharmaceutical formulation of LSD is MM120. Its primary mechanism is to promote neuroplasticity in the brain, potentially altering negative thought patterns. It also increases communication between brain regions that may address the rigid thinking that underlies GAD. How effective is MM120? In an earlier phase of the study, published in JAMA, the effects of a single dose of MM120 were evaluated over a 12-week period in approximately 200 participants with moderate-to-severe generalized anxiety disorder. The drug significantly alleviated symptoms, reducing them by five to six points on the anxiety scale in addition to the effects of placebo. That's quite significant and enough to reclassify moderate generalized anxiety disorder as mild in some cases. Were there side effects? Participants were carefully monitored by medical staff during the period after the drug was administered. Side effects were generally mild or moderate and included hallucinations, visual distortions, nausea, and headache. It's important to note, these were more prevalent using the highest dosage -- which we will not be using since it was found to be no more effective. Nausea is a common side effect with psychedelics, but this was reduced by restricting participants to a light breakfast and treating them proactively with an anti-nausea medication. What challenges do you face recruiting participants for the study? We are looking for people with moderate-to-severe general anxiety disorder, so typically those with disabling symptoms who are reluctant to leave their home. Ironically, people who would best qualify are least likely to show up. Participants are screened by very skilled clinicians who probe and observe body language and carefully build a rapport. We hope this builds trust and enables participants to be vulnerable and reflective.

Clinical ResultPhase 2

100 Deals associated with Paroxetine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Paroxetine Hydrochloride	N06AB05	DB00715

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Premenstrual Dysphoric Disorder	United States	Apotex, Inc.	28 Aug 2003
Panic	Japan	GlaxoSmithKline KK	22 Sep 2000
Anxiety Disorders	Brazil	Libbs Farmacêutica Ltda.	22 Dec 1999
Generalized anxiety disorder	United States	Apotex, Inc.	25 Jun 1997
Stress Disorders, Post-Traumatic	United States	Apotex, Inc.	25 Jun 1997
Depressive Disorder	China	Sino-American Tianjin SmithKline & French Lab Ltd.	01 Jan 1995
Depressive Disorder, Major	United States	Apotex, Inc.	29 Dec 1992
Obsessive-Compulsive Disorder	United States	Apotex, Inc.	29 Dec 1992
Panic Disorder	United States	Apotex, Inc.	29 Dec 1992
Phobia, Social	United States	Apotex, Inc.	29 Dec 1992

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hearing Loss	Phase 2	United Kingdom	GlaxoSmithKline Research & Development Ltd.	21 Sep 2006
Tinnitus	Phase 2	United Kingdom	GlaxoSmithKline Research & Development Ltd.	21 Sep 2006
Parkinson Disease	Phase 2	United States	GSK Plc	01 Jun 2003
Depressive Disorder, Treatment-Resistant	Clinical	United States	GSK Plc	01 Dec 2003
Neoplasms	Preclinical	China	Shanghai University of Traditional Chinese Medicine	27 Jan 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06231745 (Pubmed \| Drug Des Devel Ther)	Phase 4	Rheumatoid Arthritis	100	Paroxetine + csDMARDs	ifdktgmued(sxotszwhds): P-Value = 0.005 View more	Positive	01 Dec 2025
				csDMARDs + Placebo
NCT05470465 (CTgov)	Phase 1	Hypercarbia	27	Placebo+Oxycodone (Treatment A: Placebo)	dkvgzpyijt(rsapuuggsy) = cvxzcotxgx klbiogbeeu (vxhzgnesql, iyfjhtotke - cxlrludynw) View more	-	22 May 2025
				Paroxetine+Oxycodone (Treatment B: Paroxetine)	dkvgzpyijt(rsapuuggsy) = gjohsweocj klbiogbeeu (vxhzgnesql, sotjpptjrn - krwetwzdly) View more
NCT06065735 (CTgov)	Phase 1	Anxiety Disorders	38	Paroxetine (Participants Who Received Paroxetine 20 mg)	uxdmhtfhmz(emboyzrtcp) = ruvojmvsbo ujzeeetpxj (bndhsfdinv, 7.37) View more	-	16 Dec 2024
				Paroxetine (Participants Who Received Paroxetine 40 mg)	uxdmhtfhmz(emboyzrtcp) = zcdmtajoha ujzeeetpxj (bndhsfdinv, 10.82) View more
WCD2023	Not Applicable	Rosacea \| Erythema	97	Paroxetine 25 mg	agzlwenzdg(ihmsnitjgw) = hhfviglebs nnpbnmrgho (xxktityodn ) View more	Positive	04 Jul 2023
				Placebo	agzlwenzdg(ihmsnitjgw) = ghivumdkuf nnpbnmrgho (xxktityodn ) View more
NCT04311463 (CTgov)	Phase 1	Anxiety Disorders	38	Paroxetine (Paroxetine 20 mg (Test A))	ccfsrcgzgg(qlirbombrf) = bqtnkonkun eryicfiipw (pwrhqzbvzd, 5.872) View more	-	20 Jan 2022
				Paroxetine (Paroxetine 20 mg (Reference B))	ccfsrcgzgg(qlirbombrf) = clmyxixjru eryicfiipw (pwrhqzbvzd, 6.554) View more
NCT03274752 (Pubmed \| JAMA Cardiol)	Phase 2	Anterior Wall Myocardial Infarction	-	Paroxetine	ojmzqwsngi(srszdcyxkd) = iqbnsfkpdc mfynjulxba (qzwvdvlgem )	Negative	01 Oct 2021
				Placebo	ojmzqwsngi(srszdcyxkd) = uhnnrzmklf mfynjulxba (qzwvdvlgem )
UEGW2018	Not Applicable	Dyspepsia	-	Fluoxetine	bsapofmcdd(veqzzdqwtv) = deexkhozdb svhdprsmak (vsylmzyxyg )	-	01 Oct 2018
				Flupenthixol melitracen	bsapofmcdd(veqzzdqwtv) = fmhyqsauvv svhdprsmak (vsylmzyxyg )
NCT00246441 (CTgov)	Phase 4	Alcoholism \| Phobia, Social	42	Paroxetine (Paroxetine)	xupgqzmqac(folsibmjvc) = yvvrniwymo tlevbphjsl (mcbhzgyqmc, 14.9) View more	-	27 Sep 2018
				Placebo (Placebo)	xupgqzmqac(folsibmjvc) = zokbhfmhnk tlevbphjsl (mcbhzgyqmc, 18.5) View more
NCT00420641 (CTgov)	Phase 2	Depressive Disorder, Major	492	Placebo	jrwduudyvh(iqirenbanu) = bbmpzmrblj sqttlnjgwh (txkjzfckbs, 9.97) View more	-	05 Feb 2018
NCT01681849 (CTgov)	Phase 4	Stress Disorders, Post-Traumatic	91	Positron Emission Tomography (PET) Imaging+Paroxetine (Paroxetine Group)	nwsyspfofb(vgegazqihv) = bzbthjbugj fsyuplcwho (cbnuxdyxxx, 10) View more	-	28 Jun 2017
				Placebo+Paroxetine (Placebo Group)	nwsyspfofb(vgegazqihv) = wrrehpsopa fsyuplcwho (cbnuxdyxxx, 5) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis